Don’t want to miss any of the articles, news and links published on Highlight HEALTH (Discover the Science of Health), Highlight HEALTH 2.0 (Following Web 2.0 in Health and Medicine) and the Highlight HEALTH Web Directory?
Maybe you’ve a recent visitor … maybe you’ve been reading much longer. Whichever the case, there’s a number of ways to access content on the Highlight HEALTH Network. From RSS feeds to e-mail alerts to social networks, there’s bound to be a resource that works best for you.
I’d also love to get your feedback in the comments below to help keep improving the Highlight HEALTH Network.
Here’s seven ways to connect with the Highlight HEALTH Network
RSS feed
Use an RSS feed reader? Subscribe to the full text Highlight HEALTH Network RSS feed using your favorite RSS feed reader.
E-mail alerts
Receive e-mail alerts of new articles and links on the Highlight HEALTH Network.
Facebook
Are you a member of Facebook? Check out the Highlight HEALTH Network Facebook page. Become a fan and join in the conversation!
Twitter
Are you a Twitter user? Follow Highlight HEALTH Network posts on Twitter.
Social Bookmarking
At the bottom of every article on Highlight HEALTH and Highlight HEALTH 2.0 there’s a “Bookmark and Share” link. By clicking on it, you can bookmark the post to one of many sites, including del.icio.us, Google Bookmarks, StumbleUpon and Newsvine. These sites make it easy to save or share an interesting article.
Apple Dashboard widget
Use a Mac? The Highlight HEALTH Network RSS Dashboard Widget provides one-click access to the latest posts on the Highlight HEALTH Network. The widget is designed for use on the Apple Dashboard. Version 2.0 of the Highlight HEALTH Network RSS Dashboard widget includes content from Highlight HEALTH 2.0.
The Highlight HEALTH Network RSS Dashboard widget is now listed on
Apple.com.
You can download the widget
here.
Offline
Want to read content offline? Beneath the tags of every article on Highlight HEALTH and Highlight HEALTH 2.0, there is a “Print Post” link, which displays a printable version of the story, including all hyperlinks. Don’t have time to read online? Print it out and take it with you.
Additionally, the Highlight HEALTH Network now offers a new and completely free professional resource. Browse a free selection of biotechnology and pharmaceutical magazines, white papers, downloads and podcasts. Topics include genetics, bioinformatics and genomics. No credit cards, coupons or promo codes required!
Participate
You can participate in the Highlight HEALTH Network community by leaving your thoughts or questions in the comment section below every article on Highlight HEALTH and Highlight HEALTH 2.0. I try to reply to all comments. You can also e-mail me or use the contact form.
Interested in guest posting? I’m always looking for people with an interest in Web 2.0 and Health/Medicine to contribute articles for Highlight HEALTH 2.0 and the hundreds of daily readers. Please e-mail me if you’re interested.
Get connected
Don’t miss out on any of the great content on the Highlight HEALTH Network. Choose the resource(s) that work best for you and get connected today!
Bookmark or Share
The 2008 NF Conference was held last weekend (June 6 — 10) in Bonita Springs, Florida. The preeminent annual meeting provides a forum for basic and clinical neurofibromatosis (NF) investigators to present their research (pronounced noor-oh-fahy-broh-muh-toh-sis). The conference was attended by over 200 researchers from around the world
This year’s theme — Genes to Complications to Treatments — highlighted the progress being made in NF research and clinical care, as well as the research programs of the Children’s Tumor Foundation. Last year’s NF Conference focused on models, mechanisms and therapeutic targets.
The neurofibromatoses are familial cancer syndromes that predispose individuals to the development of a variety of benign and malignant tumors in the central and peripheral nervious systems. The disorders cause tumors to grow along various types of nerves and can also affect the development of bones and skin. Neurofibromatosis has been classified into three distinct types:
-
Neurofibromatosis type 1 (NF1) occurs in 1:3,500 births and is caused by a mutation of the NF1 gene on chromosome 17q11.2. NF1 diagnostic criteria (two or more) include cafe-au-lait macules, freckling, optic glioma, Lisch nodules, bony abnormalities, a first-degree relative with NF1, two or more benign nerve sheath tumors (neurofibromas) of any type, or at least one plexiform neurofibroma [1-2].
At least 95% of NF1 patients develop benign tumors called neurofibromas [3], which may be disfiguring or associated with pain and neurological defect. As there is no cure for neurofibromatosis, the only therapy is surgical removal of the tumor and associated nerve. Approximately 6 — 13% of NF1 patients will progress and develop a malignant peripheral nerve sheath tumor (MPNST), an aggressive sarcoma that has a high mortality rate (~ 50%) [4].
-
Neurofibromatosis type 2 (NF2) occurs in 1:25,000 births and is caused by a mutation of the NF2 gene on chromosome 22q12. Ninety percent of NF2 patients develop bilateral vestibular schwannomas and/or spinal schwannomas. Enlarging schwannomas can compress adjacent structures, resulting in deafness or other neurologic deficits depending on their location. Surgical removal of these tumors is difficult, often resulting in patient morbidity. Although 95% of schwannomas occur sporadically, multiple schwannomas are the hallmark of inherited NF2 [5].
-
Schwannomatosis occurs in 1:40,000 patients and, in contrast to NF2, develop multiple peripheral schwannomas, but not schwannomas of the vestibular nerve. Schwannomas in schwannomatosis patients are often associated with severe, intractable neuropathic pain and sometimes numbness, tingling and weakness. It was believed that a germline mutation in an unidentified gene predisposes patients to NF2 mutation [6]. Recently, the INI1 gene was identified as a possible schwannomatosis gene [7-8].
Both NF1 and NF2 are tumor suppressor genes.
The Children’s Tumor Foundation (CTF) is dedicated to ending neurofibromatosis through research. The CTF has funded NF research for over 25 years with the goal of identifying NF drug therapies and improving the lives of those living with the disorder. The Foundation also endeavors to increase public awareness of NF and provides resources for NF patients and their families.
For more information on NF, visit the Children’s Tumor Foundation and Neurofibromatosis Cafe.
CTF medical podcasts are also available.
References
-
Riccardi VM. The prenatal diagnosis of NF-1 and NF-2. J Dermatol. 1992 Nov;19(11):885-91.
View abstract
-
Gutmann et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997 Jul 2;278(1):51-7.
View abstract
-
Rasmussen and Friedman. NF1 gene and neurofibromatosis 1. Am J Epidemiol. 2000 Jan 1;151(1):33-40.
View abstract
-
Evans et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002 May;39(5):311-4.
View abstract
-
Evans et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet. 1992 Dec;29(12):841-6.
View abstract
-
Jacoby et al. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet. 1997 Dec;61(6):1293-302.
View abstract
-
Hulsebos et al. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am J Hum Genet. 2007 Apr;80(4):805-10. Epub 2007 Feb 16.
View abstract
-
Hadfield et al. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet. 2008 Jun;45(6):332-9. Epub 2008 Feb 19.
View abstract
Bookmark or Share
Share on Facebook
Add to Connotea
Stumble it
add to delicious
Loading ...
